HTFL Heartflow, Inc. Insider Trading

HTFL CEO John C.M. Farquhar sold 22,562 shares at $27.75 (10b5-1 plan); stock down 36.5% from 52-week high, company unprofitable.

John C.M. Farquhar sold 22,562 shares under a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, reducing his holdings by 4.9% from 457,935 to 435,373 shares at $27.75 on 2026-07-10. The sale is scheduled and non-discretionary under the 10b5-1 framework, so it reflects prior planning rather than current market judgment. Contextually, the stock has declined 36.5% from its 52-week high of $41.22 and 21.3% over the prior 30 days; Heartflow remains unprofitable with a net income of $-27,380,000 despite 39.9% annual revenue growth to $52,587,000. His prior open-market sales across tickers have averaged a 90-day return of +5.4%, suggesting past sales preceded stock appreciation, though specific outcomes at HTFL are limited due to the recency of most trades in his same-ticker history.

CEO John C.M. Farquhar sells 38,900 HTFL shares at $35.00 ($1.4M) under 10b5-1 plan; stock now -13.5% from 52-week high.

CEO John C.M. Farquhar sold 38,900 shares of Heartflow for $1,361,500 on 2026-06-24, reducing his holdings from 496,835 to 457,935 shares, a 7.8% reduction. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, making it scheduled rather than discretionary. At the sale price of $35.00, the stock was 13.5% below its 52-week high of $41.22, though it has gained 21.8% over the past 30 days and 44.4% over 90 days. The company itself remains unprofitable with net income of negative $27,380,000 on revenue of $52,587,000 in the latest quarter, though it is growing revenue at 39.9% annually. His prior four sales at HTFL show mixed near-term outcomes: the most recent sale on 2026-06-10 is not yet measurable; earlier sales showed a 30-day return of +10.4% and a 90-day return of +7.0% from the 2026-04-10 sale, but a 30-day decline of -24.3% from the 2026-02-10 sale.

CEO John C.M. Farquhar sold 22.6K shares of HTFL at $28.50 under pre-arranged 10b5-1 plan; stock now $33.24

John C.M. Farquhar, CEO of Heartflow Inc., sold 22,562 shares at $28.50 on 2026-06-10 under a 10b5-1 trading plan adopted on 2025-09-12, reducing his holdings from 519,397 shares to 496,835 shares. The transaction was scheduled rather than discretionary. The stock currently trades at $33.24, above the sale price, and has posted a 90-day gain of +62.2%, though the CEO's prior same-ticker sales (three trades at HTFL) showed mixed 30-day outcomes ranging from -24.3% to +10.4%. The company remains unprofitable with net income of $-27.4M on quarterly revenue of $52.6M, though it demonstrated +39.9% annual revenue growth, providing limited visibility into valuation sustainability.

CEO Farquhar sells 22,562 shares at $29.12 amid unprofitable operations and mixed prior exit timing.

CEO John Farquhar is selling shares as Heartflow faces a challenging financial backdrop — the company lost over $116 million annually with negative earnings, though revenue is growing briskly. This is the third open-market sale at Heartflow within the past three years for Farquhar, who has yet to purchase shares on the open market as CEO. Farquhar's prior two exits at this company show conflicting timing: at the 30-day mark, one sale proved well-timed (the stock fell afterward) and one was poorly timed (the stock rose); over 90 days, both prior sales were poorly timed as the stock recovered and gained. The current sale occurs as the stock trades notably below its 52-week high, having retreated from a stronger recent period. Without additional cluster context or material events disclosed in the filing itself, this appears to be a routine portfolio management move from the CEO, though the pattern of repeated selling without any offsetting purchases warrants tracking against near-term company catalysts.

Bain Capital Life Sciences divests ~2M shares of HTFL across four tranches totaling ~$58.9M in late April.

Bain Capital Life Sciences, a major institutional shareholder owning roughly 10% of HeartFlow, executed a multi-day liquidation of approximately 2 million shares across late April. This is a portfolio management decision by an investment fund, not insider sentiment from operational leadership—Bain holds no officer or director roles. The timing coincides with the stock trading well below its recent highs after a period of volatility, suggesting Bain may have chosen to exit while the stock stabilized around current levels rather than waiting for a recovery. HeartFlow itself remains unprofitable with significant quarterly losses, though revenue is growing at a strong pace, making the company a classic high-growth, pre-profitability biotech. Institutional holders like Bain often harvest gains or rebalance positions based on portfolio targets rather than company-specific concerns, so this sale alone does not signal distress—it's routine fund management of a mature stake.

CEO Farquhar sold 22,562 shares of HTFL at $26.72; stock now at $29.05 (30-day +41.8%), company unprofitable at -$50.9M net income.

CEO John C.M. Farquhar sold 22,562 shares (22.6K shares) at $26.72 on 2026-04-10, reducing his stake from 571,725 to 549,163 shares (-3.9%). The sale occurred ahead of a significant 30-day rally of +41.8%, meaning the stock price rose substantially after the transaction. Heartflow remains unprofitable with net income of -$50.9M on quarterly revenue of $46.3M, though the company shows strong annual revenue growth of +39.9%. The CEO's prior cross-ticker selling history shows an average 30-day return of -24.3%, and his prior HTFL sale on 2026-02-10 also preceded a -24.3% 30-day decline, but this current sale did not precede a similar downturn—the stock rallied instead. Investors should track whether this represents a one-time portfolio adjustment at the CEO level despite the company's growth trajectory.

CMO Rogers Campbell sold 64,533 shares of HTFL at $24.64 via 10b5-1 plan; reduced stake by 44.3% to 81,002 shares

Rogers Campbell, Chief Medical Officer, executed a sale of 64,533 shares on 2026-04-01 at $24.64 per share, reducing his holdings from 145,535 shares to 81,002 shares—a 44.3% reduction in his position. This transaction was conducted under a 10b5-1 trading plan adopted on 2025-09-12, meaning it was pre-arranged and scheduled rather than a discretionary trade decision. The planned nature of the sale removes it from analysis as a signal of current conviction or concern, as the timing and size were locked in months in advance. The significant reduction in absolute share count warrants monitoring of whether the executive retains sufficient alignment with shareholder interests.

CMO Rogers Campbell sold 64.5K shares of HTFL at $25.69, reducing stake by 45.1%, in financially troubled company.

Rogers Campbell, Chief Medical Officer of Heartflow Inc., executed a substantial sale of 64,533 shares at $25.69 on 2026-03-19, reducing his holdings from 143,051 shares to 78,518 shares. The company remains unprofitable with net income of $-50.9M against revenue of $46.3M in its latest quarter, despite annual revenue growth of +39.9%. The stock trades 32.8% below its 52-week high of $39.91, and Campbell's prior sell at this ticker produced a -16.3% 30-day return with no measurable 90-day outcome yet. This magnitude of stake reduction by a chief medical officer at a cash-burning biotech warrants investor attention to whether it reflects broader capital allocation concerns or reflects individual portfolio adjustments.

CMO Rogers Campbell sold 65,153 shares of HTFL at $24.49 on 2026-02-12 via 10b5-1 plan; post-sale holdings: 76,034 shares

Rogers Campbell, Chief Medical Officer, sold 65,153 shares at $24.49 on 2026-02-12 for $1,595,486.21 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-12. This was a scheduled, non-discretionary transaction that reduced his holdings by 46.1%, leaving 76,034 shares post-transaction. Since the trade was executed under a 10b5-1 plan established months prior, the timing reflects the plan's predetermined schedule rather than a response to current market conditions or company fundamentals. The material reduction in position size warrants tracking to understand broader insider participation trends at the company.

Heartflow CEO Farquhar sells 22,562 shares at $27.46 under pre-arranged 10b5-1 plan

Farquhar, as Chief Executive Officer, sold 22,562 shares of Heartflow at $27.46 on 2026-02-10 for a total value of $619,552.52, reducing his holdings from 614,218 shares to 591,656 shares—a -3.7% reduction in his position. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, meaning it was scheduled in advance and not a discretionary trade decision. Since the sale is governed by a 10b5-1 plan executed on a predetermined schedule, it does not reflect contemporaneous judgment about the stock's valuation or company prospects. The CEO retains substantial holdings of 591,656 shares post-transaction.